Acurx Pharmaceuticals Secures Japanese Patent for Novel Antibiotic Technology

Acurx Pharmaceuticals, Inc, a late-stage biopharmaceutical company specializing in novel antibiotics, has been granted a new patent by the Japanese Patent Office (JPO) in January 2025. This patent covers DNA Polymerase IIIC inhibitors, including compositions-of-matter, surface coatings, and pharmaceutical compositions for treating Gram-positive bacterial infections. This latest addition strengthens Acurx’s intellectual property portfolio, which already includes three U.S. patents, one Israeli patent, and ongoing filings in other countries. The company’s ACX-375C program, a key part of its antimicrobial innovations, is now protected under this newly granted patent.

Executive Chairman Robert J. DeLuccia emphasized the significance of this milestone, highlighting the company’s AI-driven drug discovery platform and ongoing Phase 3 program for ibezapolstat, a minimally absorbed oral antibiotic for Clostridioides difficile infection (CDI). With positive regulatory guidance from the EMA and alignment with the FDA, Acurx is preparing for two pivotal Phase 3 trials comparing ibezapolstat to vancomycin. The trials will evaluate ibezapolstat’s efficacy in treating CDI and its potential to prevent recurrence. If successful, these findings could lead to a European marketing authorization application (MAA), reinforcing Acurx’s leadership in antibiotic innovation.